Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Recruiting

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone TherapySafety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Sponsor:

James A. Tumlin, MD

Code:

NCT03502031

Conditions

Renal Insufficiency, Chronic

Diabetic Nephropathy Type 2

Eligibility Criteria

Sex: All

Age: 75+

Healthy Volunteers: Not accepted

Interventions

Renin-Angiotensin (RAAS) alone

Renin-Angiotensin (RAAS) blockers in combination with Spironolactone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-28. This information was provided to ClinicalTrials.gov by James A. Tumlin, MD on 2022-10-28.